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Chemical reagents were purchased from commercial sources and were used without further purification 
unless noted otherwise. Moisture sensitive reactions were performed under nitrogen or argon atmosphere. 
CH2Cl2 was dried over calcium hydride. Methylamine was used as 2 M solution in THF for peptoid 
synthesis and glycine tert-butyl ester hydrochloride was neutralized with aq. 1 N NaOH and extracted 
with DCM prior to use. Grubbs catalyst 1st generation (G1), Grubbs catalyst 2nd generation (G2) and 
Hoveyda-Grubbs catalyst 2nd generation (HG2) were purchased from Aldrich. Rink Amide AM resin LL 
(100-200 mesh, 0.4 mmol/g) and TentaGel MB RAM (0.4 mmol/g) were purchased from Novabiochem 
and Rapp Polymere, respectively. Analytical TLC was performed on Merck 60 F254 silica gel plate (0.25 
mm thickness), and visualization was done with UV light and/or by spraying with a 5% solution of 
phosphomolybdic acid followed by charring with a heat gun. Flash column chromatography was 
performed on Merck 60 silica gel (70–230 mesh). The 1H NMR and 13C NMR spectra were recorded on a 
Varian Unity-Inova 500 MHz spectrometer. Me4Si was used as internal standard for 1H NMR. Reverse-
phase HPLC experiments were conducted through an ACE 5 C18-HL (250 x 4.6 mm) reverse phase 
column on a Shimadzu binary HPLC system equipped with a UV-visible detector at 220 nm. The typical 
flow rate for analytical HPLC was 1 mL/min. In all cases, a gradient elution of water/acetonitrile with 
0.05% TFA was used. Conversion efficiency for CM reactions was determined by HPLC analysis based 
on the peak integration of glycopeptoid over the total peak integration of unreacted starting peptoid, 
dimerized peptoid, and glycopeptoid. MALDI-TOF MS was performed on a Voyager-DE STR 
biospectrometry workstation (Applied Biosystems) with α-cyano-4-hydroxycinnamic acid as a matrix. 
The peptoids were synthesized in an incubator shaker (JEIO TECH, model SI-600R) or in a microwave 
oven (Daewoo, model KR-B200R). The microwave reactions were performed at a power of 100 W for 
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16: R = Ac; X = H; n = 1
17: R = Ac; X = H; n = 2 
18: R = Ac; X = H; n = 3
19: R = Ac; X = Me; n = 2
20: R = Bz; X = H; n = 1
21: R = Bz; X = H; n = 2 
22: R = Bz; X = H; n = 3
23: R = Bz; X = Me; n = 2
Galactoside
24: R = Bz; X = H; n = 1
25: R = Bz; X = H; n = 2 
26: R = Bz; X = H; n = 3
27: R = Bz; X = Me; n = 2
Glucoside
28: R = Bz; X = H; n = 1
29: R = Bz; X = H; n = 2 
30: R = Bz; X = H; n = 3
4, 8, 12: Man(OAc) 4
5, 9, 13: Man(OBz) 4
6, 10, 14: Gal(OBz) 4
7, 11, 15: Glu(OBz) 4
1: Man, 2: Gal, 3: Glu
 
 
- General procedure for glycosylation: To a solution of glycosyl trichloroacetimidate donor (12,1 
13,2 14,2a,3 and 15,2a,3b 5.0 mmol) and glycosyl acceptor (allyl alcohol, 3-buten-1-ol, 4- penten-1-ol, or 3-
methyl-3-buten-1-ol; 3.0 eq.) in dry DCM (20 mL) was added TMSOTf (0.1 eq.) at −20 °C. The reaction 
mixture was stirred for overnight. After completion of the reaction, triethylamine (1.0 mL) was added. 
The reaction mixture was concentrated in vacuo to give thick pale yellow oil. Crude product was purified 
by column chromatography (ethyl acetate: hexane, 1: 9 to 1: 4) to afford compounds 16–30 as transparent 
foamy compounds in 75-90 % yield. 
 








Allyl 2,3,4,6-tetra-O-acetate-α-D-mannopyranoside4 (16): Rf 0.21 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 1.98, 2.03, 2.10, 2.14, (12H, s, 4 × OAc), 4.02 (1H, m, H-5), 4.04 (1H, d, J = 5.0 
Hz, CHHCH=CH2), 4.10 (1H, d, J = 11.5 Hz, CHHCH=CH2), 4.18 (1H, dd, J = 12.5, 4.0 Hz, H-6A), 4.28 
(1H, dd, J = 12.0, 5.5 Hz, H-6B), 4.86 (1H, s, H-1), 5.20 (1H, m, CH=CHH), 5.25 (1H, d, J = 3.0 Hz, H-2), 
5.28 (1H, t, J = 9.9 Hz, H-4), 5.32 (1H, m, CH=CHH) 5.36 (1H, dd, J = 10.0, 3.0 Hz, H-3), 5.85–5.93 (1H, 
m, CH=CHH). 13C NMR (125 MHz, CDCl3): δC = 20.65, 20.67, 20.70, 20.86 (4 × OAc), 62.45 (C-6), 
S5 
 
66.18 (C-2), 68.52 (C-3), 68.64 (C-4), 69.61 (C-5), 94.76 (C-1), 118.43, 132.89, 169.71, 169.86, 170.02, 








Butenyl 2,3,4,6-tetra-O-acetate-α-D-mannopyranoside (17): Rf 0.24 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 1.98, (3H, s), 2.04 (3H, s), 2.09 (3H, s), 2.15 (3H, s), 2.35–2.38 (2H, m), 3.52 
(1H, dd, J = 15.5, 7.0 Hz), 3.72 (1H, dd, J = 17.0, 7.0 Hz), 3.99 (1H, m), 4.11 (1H, d, J = 5.0 Hz), 4.27 
(1H, dd, J = 11.5, 4.5 Hz), 4.81 (1H, s), 5.06–5.13 (2H, m), 5.24 (1H, d, J = 3.0 Hz), 5.26 (1H, t, J = 9.9 
Hz), 5.34 (1H, dd, J = 10.0, 3.0 Hz), 5.80 (1H, m). 13C NMR (125 MHz, CDCl3): δC = 20.92, 20.93, 20.96, 
21.12, 33.93, 62.74, 66.46, 68.01, 68.73, 69.34, 69.89, 97.79, 117.41, 134.57, 170.03, 170.17, 170.34, 








Pentenyl 2,3,4,6-tetra-O-acetate-α-D-mannopyranoside5 (18): Rf 0.44 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 1.69–1.73 (2H, m), 1.99, (3H, s), 2.04 (3H, s), 2.10 (3H, s), 2.13–2.15 (5H,  m), 
3.47 (1H, dd, J = 15.5, 5.5 Hz), 3.71 (1H, dd, J = 16.5, 7 Hz), 3.97–4.00 (1H, m), 4.11 (1H, d, J = 11.5 
Hz), 4.27 (1H, dd, J = 11.5, 4.5 Hz), 4.80 (1H, s), 4.98–5.06 (2H, m), 5.23 (1H, d, J = 3.0 Hz), 5.27 (1H, t, 
J = 10.0 Hz), 5.35 (1H, dd, J = 10.0, 3.0 Hz), 5.77–5.83 (1H, m). 13C NMR (125 MHz, CDCl3): δC = 
20.90, 20.92, 20.95, 21.11, 28.61, 30.38, 62.75, 66.48, 67.97, 68.67, 69.34, 69.91, 97.84, 115.40, 137.93, 









3-Methyl-3-butenyl 2,3,4,6-tetra-O-acetate-α-D-mannopyranoside (19): Rf 0.44 (EtOAc–hexane, 1 : 2); 
1H NMR (500 MHz, CDCl3) δH = 1.75 (3H, s), 1.98, (3H, s), 2.04 (3H, s), 2.09 (3H, s), 2.15 (3H, s), 2.33 
(2H, t, J = 7.0 Hz) 3.60 (1H, dd, J = 15.5, 7.0 Hz), 3.79 (1H, dd, J = 16.5, 7.0 Hz), 3.98–4.00 (1H, m), 
4.09 (1H, dd, J = 13.5, 3.5 Hz), 4.27 (1H, dd, J = 12.5, 5.0 Hz), 4.74 (1H, s), 4.82 (2H, d, J = 9.5 Hz), 
5.22 (1H, d, J = 3.0 Hz), 5.26 (1H, t, J = 9.5 Hz), 5.34 (1H, dd, J = 10.0, 3.0 Hz). 13C NMR (125 MHz, 
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CDCl3): δC = 20.91, 20.93, 20.95, 21.13, 22.96, 37.57, 62.76, 66.45, 67.16, 68.78, 69.33, 69.94, 97.74, 
112.38, 142.22, 169.39, 170.11, 170.31, 170.87. MALDI-TOF: m/z: calcd for C19H23O10Na 439.2; found 








Allyl 2,3,4,6-tetra-O-benzoyl-α-D-mannopyranoside6 (20): Rf 0.53 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 4.18 (1H, dd, J = 12.5, 5.5 Hz), 4.36 (1H, dd, J = 13.5, 5.0 Hz), 4.64–4.51 (2H, 
m), 4.71 (1H, dd, J = 11.5, 2.5 Hz), 5.15 (1H, d, J = 2.5 Hz), 5.27 (1H, dd, J = 10.5, 1.0 Hz), 5.37 (1H, dd, 
J = 17.0, 1.5 Hz), 5.72–5.73 (1H, m), 5.94 (1H, dd, J = 10.0, 3.5 Hz), 5.97–6.04 (1H, m), 6.12 (1H, t, J = 
10.5 Hz), 7.25–7.60 (12H, m, Ph), 7.83–8.11 (8H, m, Ph). 13C NMR (125 MHz, CDCl3): δC = 63.14, 
67.19, 69.21, 70.34, 70.79, 96.99, 118.76, 128.54, 128.69, 128.82, 129.20, 129.32, 129.55, 129.96, 129.97, 







Butenyl 2,3,4,6-tetra-O-benzoyl-α-D-mannopyranoside7 (21): Rf 0.56 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 2.49 (2H, d, J = 7.0 Hz), 3.66–3.68 (1H, m), 3.86–3.89 (1H, m), 4.46 (1H, m), 
4.51 (1H, d, J = 12.0 Hz), 4.69 (1H, d, J = 12.0 Hz), 5.12 (1H, s), 5.16 (2H, m), 5.70 (1H, t, J = 3.0 Hz), 
5.91–5.93 (2H, m), 6.10 (1H, t, J = 10.5 Hz), 7.25–7.58 (12H, m, Ph), 7.83–8.11 (8H, m, Ph). 13C NMR 
(125 MHz, CDCl3): δC = 34.07, 63.18, 67.22, 68.22, 69.16, 70.36, 70.81, 95.01, 97.88, 117.50, 125.83, 
126.73, 128.55, 128.69, 128.83, 129.22, 129.32, 129.57, 129.97, 130.05, 130.09, 133.26, 133.32, 133.42, 








Pentenyl 2,3,4,6-tetra-O-benzoyl-α-D-mannopyranoside8 (22): Rf 0.60 (EtOAc–hexane, 1 : 2); 1H 
NMR (500 MHz, CDCl3) δH = 1.83 (2H, m), 2.22 (2H, m), 3.60 (1H, dd, J = 16.0, 6.5 Hz), 3.86 (1H, dd, J 
= 16.5, 6.5 Hz), 4.41–4.45 (1H, m), 4.48 (1H, dd, J = 12.5, 5.0 Hz), 4.70 (1H, dd, J = 12.5, 2.5 Hz), 5.03 
(1H, d, J = 10.0, Hz), 5.07–5.11 (2H, m), 5.69–5.70 (1H, m), 5.86 (1H, m), 5.94 (1H, dd, J = 10.0, 3.5 
Hz), 6.12 (1H, t, J = 10.5 Hz), 7.25–7.61 (12H, m, Ph), 7.83–8.11 (8H, m, Ph). 13C NMR (125 MHz, 
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CDCl3): δC = 28.75, 30.49, 63.19, 67.26, 68.24, 69.10, 70.34, 70.85, 97.93, 115.51, 128.54, 128.67, 
128.82, 129.24, 129.35, 129.61, 129.97, 130.05, 130.09, 130.12, 133.30, 133.40, 133.66, 133.68, 138.02, 









3-Methyl-3-butenyl 2,3,4,6-tetra-O-benzoyl-α-D-mannopyranoside (23): Rf 0.46 (EtOAc–hexane, 1 : 
2); 1H NMR (500 MHz, CDCl3) δH = 1.81 (3H, s), 2.43–2.46 (2H, m), 3.73 (1H, dd, J = 10.0, 7.0 Hz), 
3.96 (1H, dd, J = 10.0, 6.5 Hz), 4.44–4.46 (1H, m), 4.50 (1H, dd, J = 12.5, 5.0 Hz), 4.71 (1H, dd, J = 11.5, 
2.0 Hz), 4.81 (1H, s), 4.86 (1H, s), 5.13 (1H, d, J = 1.5 Hz), 5.70 (1H, m), 5.94 (1H, dd, J = 10.0, 3.5 Hz), 
6.10 (1H, t, J = 10.0 Hz), 7.25–7.61 (12H, m, Ph), 7.83–8.11 (8H, m, Ph). 13C NMR (125 MHz, CDCl3): 
δC = 28.30, 37.69, 63.21, 67.23, 67.44, 69.19, 70.34, 70.86, 97.81, 112.44, 128.53, 128.67, 128.82, 129.24, 
129.35, 129.60, 129.97, 130.05, 130.09, 130.10, 133.29, 133.39, 133.66, 133.69, 142.32, 165.69, 165.70, 








Allyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside (24): Rf 0.55 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 4.20 (1H, dd, J = 12.5, 6.0 Hz), 4.32 (1H, t, J = 8.0 Hz), 4.40–4.52 (2H, m), 4.68 
(1H, dd, J = 12.0, 7.0 Hz), 4.89 (1H, d, J = 7.5, Hz), 5.14 (1H, d, J = 11.0 Hz), 5.24 (1H, d, J = 17.5, Hz), 
5.61 (1H, dd, J = 11.0, 4.0 Hz), 5.83 (2H, m,), 6.00 (1H, d, J = 3.0 Hz), 7.23–7.62 (12H, m, Ph), 7.77–
8.10 (8H, m, Ph). 13C NMR (125 MHz, CDCl3): δC = 60.39, 62.04, 68.12, 69.77, 70.29, 71.31, 94.75, 
100.23, 118.02, 128.28, 128.37, 128.47, 128.62, 128.74, 128.99, 129.37, 129.41, 129.72, 129.75, 129.77, 
130.03, 133.22, 133.28, 133.31, 133.33, 133.60, 165.27, 165.60, 165.71, 166.06. MALDI-TOF: m/z: calcd 








Butenyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside (25): Rf 0.60 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 2.29–2.36 (2H, m), 3.64 (1H, dd, J = 17.5, 7.5 Hz), 4.02 (1H, dd, J = 17.0, 7.5 
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Hz), 4.34 (1H, t, J = 6.0, Hz), 4.43 (1H, dd, J = 11.0, 7.0 Hz), 4.69 (1H, dd, J = 12.0, 7.0 Hz), 4.81–4.85 
(2H, m), 4.97 (1H, d, J = 15.5, Hz), 5.60 (1H, dd, J = 11.1, 4.0 Hz), 5.79 (1H, dd, J = 11.2, 7.5 Hz), 5.99 
(1H, d, J = 4.0 Hz), 6.13 (1H, dd, J = 11.0, 4.0 Hz), 7.23–7.65 (12H, m, Ph), 7.77–8.13 (8H, m, Ph). 13C 
NMR (125 MHz, CDCl3): δC = 33.84, 62.01, 68.13, 68.54, 69.45, 69.68, 71.30, 90.68, 101.70, 116.77, 
128.33, 128.40, 128.61, 128.74, 128.83, 128.99, 129.28, 129.47, 129.76, 129.94, 130.05, 133.18, 133.29, 
133.48, 133.73, 134.26, 165.49, 165.60, 165.7, 166.07. MALDI-TOF: m/z: calcd for C38H34O10Na 673.2; 








Pentenyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside8a,9 (26): Rf 0.61 (EtOAc–hexane, 1 : 2); 1H 
NMR (500 MHz, CDCl3) δH = 1.60–1.73 (3H, m), 1.94–2.03 (2H, m), 3.60 (1H, dd, J = 16.5, 7.0 Hz), 
3.98 (1H, dd, J = 16.0, 6.0 Hz), 4.32 (1H, t, J = 6.5 Hz), 4.43 (1H, dd, J = 10.0, 4.5 Hz), 4.69 (1H, dd, J = 
12.0, 7.0 Hz), 4.80–4.84 (2H, m), 5.60–5.67 (2H, m), 5.79 (1H, dd, J = 10.0, 8.0 Hz), 5.99 (1H, d, J = 4.0 
Hz), 7.24–7.61 (12H, m, Ph), 7.77–8.10 (8H, m, Ph). 13C NMR (125 MHz, CDCl3): δC = 28.55, 29.78, 
62.02, 68.15, 69.65, 69.85, 71.27, 71.75, 101.69, 114.91, 128.29, 128.38, 128.46, 128.61, 128.78, 129.04, 








3-Methyl-3-butenyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside (27): Rf 0.60 (EtOAc–hexane, 1 : 
2); 1H NMR (500 MHz, CDCl3) δH = 1.59 (3H, s), 2.27–2.31 (2H, m), 3.71 (1H, dd, J = 17.5, 8.0 Hz), 
4.08 (1H, dd, J = 15.5, 6.0 Hz), 4.35 (1H, t, J = 6.5 Hz), 4.43 (1H, dd, J = 11.0, 7.0 Hz), 4.56 (1H, s), 4.60 
(1H, s), 4.69 (1H, dd, J = 11.5, 6.5 Hz), 4.83 (1H, d, J = 9.0 Hz), 5.62 (1H, dd, J = 9.5, 2.5 Hz), 5.80 (1H, 
dd, J = 11.0, 8.0 Hz), 5.99 (1H, d, J = 2.0 Hz ), 7.22–7.61 (12H, m, Ph), 7.77–8.10 (8H, m, Ph). 13C NMR 
(125 MHz, CDCl3): δC = 22.54, 37.36, 62.03, 68.14, 68.70, 69.73, 71.30, 71.75, 101.62, 111.86, 128.28, 
128.29, 128.47, 128.61, 128.77, 129.03, 129.43, 129.49, 129.72, 129.77, 129.78, 130.04, 133.16, 133.28, 
133.29, 133.59, 141.89, 165.23, 165.42, 165.60, 166.07. MALDI-TOF: m/z: calcd for C39H36O10Na 687.2; 










Allyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranoside8a,10 (28): Rf 0.52 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 4.15–4.19 (2H, m), 4.37 (1H, dd, J = 13.0, 5.0 Hz), 4.50 (1H, dd, J = 12.5, 5.5 
Hz), 4.63 (1H, dd, J = 13.0, 4.0 Hz), 4.90 (1H, d, J = 8.0 Hz), 5.11 (1H, d, J = 8.5 Hz), 5.23 (1H, d, J = 
18.0 Hz), 5.56 (1H, dd, J = 10.0, 8.0 Hz), 5.68 (1H, t, J = 10.0 Hz), 5.76–5.83 (1H, m), 5.91 (1H, t, J = 
9.0 Hz), 7.25–7.55 (12H, m, Ph), 7.82–8.03 (8H, m, Ph). 13C NMR (125 MHz, CDCl3): δC = 63.45, 70.07, 
70.34, 72.12, 72.46, 73.22, 100.08, 118.18, 128.54, 138.60, 138.62, 138.66, 129.04, 129.05, 129.55, 









Butenyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranoside (29): Rf 0.55 (EtOAc–hexane, 1 : 2); 1H NMR 
(500 MHz, CDCl3) δH = 2.28–2.30 (2H, m), 3.61 (1H, dd, J = 16.5, 7.0 Hz), 3.97 (1H, dd, J = 15.5, 6.0 
Hz), 4.14–4.17 (1H, m), 4.51 (1H, dd, J = 11.5, 5.0 Hz), 4.65 (1H, dd, J = 11.5, 3.0 Hz), 4.82 (1H, d, J = 
9.0 Hz), 4.87 (1H, d, J = 8.0 Hz), 4.94 (1H, d, J = 18.5, Hz), 5.53 (1H, dd, J = 9.5, 8.0 Hz), 5.65–5.69 (2H, 
m), 5.90 (1H, t, J = 9.5 Hz), 7.25–7.53 (12H, m, Ph), 7.82–8.02 (8H, m, Ph). 13C NMR (125 MHz, 
CDCl3): δC = 34.08, 63.46, 69.71, 70.08, 72.11, 72.45, 73.17, 101.50, 117.00, 128.54, 128.57, 128.61, 
128.65, 129.05, 129.07, 129.63, 129.85, 129.98, 130.00, 130.02, 130.07, 133.37, 133.42, 133.47, 133.67, 




Pentenyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranoside9,11 (30): Rf 0.56 (EtOAc–hexane, 1 : 2); 1H 
NMR (500 MHz, CDCl3) δH = 1.57–1.68 (2H, m), 1.93–2.00 (2H, m), 3.55 (1H, dd, J = 16.5, 7.0 Hz), 
3.93 (1H, dd, J = 15.5, 6.0 Hz), 4.15–4.16 (1H, m), 4.50 (1H, dd, J = 12.0, 5.0 Hz), 4.65 (1H, dd, J = 11.5, 
4.0 Hz), 4.80–4.84 (3H, m), 5.53 (1H, dd, J = 10.0, 7.5 Hz), 5.60–5.69 (2H, m), 5.90 (1H, t, J = 10.0 Hz), 
7.25–7.55 (12H, m, Ph), 7.82–8.02 (8H, m, Ph). 13C NMR (125 MHz, CDCl3): δC = 28.79, 30.01, 63.47, 
69.68, 70.11, 72.18, 72.42, 73.20, 101.52, 115.15, 128.54, 128.60, 128.65, 129.06, 129.08, 129.60, 129.86, 
129.98, 130.00, 130.07, 133.36, 133.45, 133.47, 133.67, 137.97, 165.34, 165.46, 166.10, 166.41. 
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General procedure for peptoid synthesis 
Peptoids were synthesized on Rink amide AM resin LL (31-32, 37, and 49) and TentaGel MB RAM resin 
(59) by the conventional submonomer strategy.17 Peptoid syntheses were performed in 25 mL standard 
glass peptide synthesis vessels. The resins were swelled in DMF at 25 oC for 1-2 h. Then DMF was 
drained, and the beads were incubated 20% piperidine in DMF for 1 h and washed thoroughly with DMF 
(8 × 3 mL). The beads were treated with 2 M bromoacetic acid (1.0-1.5 mL) and 3.2 M DIC (1.0-1.5 mL) 
and irradiated in a microwave oven (100 W) for 3 × 12 sec with shaking for 30 sec after each pulse. The 
beads were thoroughly washed with DMF (8 × 3 mL) and then treated with primary amines (1-2 M, 2.0 
mL) in DMF in a microwave oven (100 W) for 3 × 12 sec with shaking for 30 sec after each pulse. Both 
acylation and displacement were successively repeated to form the desired peptoid sequences. To prevent 
inactivation of CM catalyst from free amines, the peptoids were capped with Boc-anhydride (10 eq.) and 
triethylamine (1.0 mL) in DCM (5.0 mL) and the beads were shaken for 2 h before being washed with 
MeOH (8 × 3.0 mL) and DCM (8 × 3.0 mL), and left to dry under vacuum for 2 h before CM. 
 
General procedure for solid-phase CM of peptoids and sugar derivatives 
- Under microwave conditions 
The bead containing peptoids (15 mg) and sugar derivatives (20 eq., 25 mM) were shaken in DCB (1.5 
mL) for 30 min. Then 5 mol% CM catalysts were added and irradiated under microwave (300 W) for 4 × 
30 sec (total 2 min) with shaking for 30 sec after each pulse. The resin was thoroughly washed with DCM 
(8 × 3.0 mL). 
- Under reflux conditions 
The bead containing peptoids (15 mg) and sugar derivatives (20 eq., 25 mM) were stirred in anhydrous 
DCM (1.5 mL) for 30 min. Then 5 mol% CM catalysts were added and refluxed at 40 °C under nitrogen 
atmosphere for 8 h. The resin was thoroughly washed with DCM (8 × 3.0 mL). 
 
General TFA cleavage procedure 
Glycopeptoid-tethered resin was suspended in a cleavage cocktail (92% TFA/5% H2O/3% TIS) for 1-2 h. 
After cleavage solution was removed by blowing N2 gas, 50% aq. acetonitrile containing 0.1% TFA was 
added and mixed uniformly. The mixture was filtered through 0.2 µm PTFE filter tip and the obtained 






DMF: N,N-dimethylformamide, DCB: 1,2-dichlorobenzene, DCM: methylene chloride, DBU: 1,8-
diazabicyclo[5.4.0]undec-7-ene, TFA: trifluoroacetic acid, TIS: triisopropylsilane, TMSOTf: 
trimethylsilyl trifluoromethanesulfonate, DIC: N,N′-diisopropylcarbodiimide, G1: Grubbs catalyst 1st 
generation, [bis(tricyclohexylphosphine) benzylidine ruthenium (IV) chloride], G2: Grubbs catalyst 2nd 
generation, [1,3-bis-(2,4,6-trimethylphenyl)-2-(imidazolidinylidene)(dichlorophenylmethylene) 
(tricyclohexylphosphine) ruthenium], HG2: Hoveyda-Grubbs catalyst 2nd generation [(1,3-bis-(2,4,6-
trimethylphenyl)-2-imidazolidinylidene) dichloro(o-isopropoxyphenylmethylene)ruthenium], CM: cross 
metathesis, HPLC: high-performance liquid chromatography, NMR: nuclear magnetic resonance, 
MALDI-TOF: matrix-assisted laser desorption/ionization-time of flight. 
 
References 
1. Woller, E. K.; Clonginger, M. J. Org. Lett., 2002, 4, 7. 
2. (a) Lee, W. S.; Kim, W.; Kim, K. T.; Chung, S. K. Bull. Korean Chem. Soc. 2011, 32, 2286. (b) Al-
Mughaid, H.; Grindley, T. B. J. Org.Chem. 2006, 71, 1390. 
3. (a) Lafont, D.; Bouchu, M. N.; Girard-Egrot, A.; Boullanger, P. Carbohydr. Res. 2001, 336, 181. (b) 
Yang, J.; Cooper-Vanosdell, C.; Mensah, E. A.; Nguyen, H. M. J. Org. Chem. 2008, 73, 794. 
4. (a) Lin, Y. A.; Chalker, J. M.; Davis, B. G. J. Am. Chem. Soc. 2010, 132, 16805. (b) Utille, J. P.; 
Priem, B. Carbohydr. Res. 2000, 329, 431. 
5. Lin, C. C.; Yeh, Y. C.; Yang, C. Y.; Chen, C. L.; Chen, G. F.; Chen, C. C.; Wu, Y. C. J. 
Am. Chem. Soc. 2002, 124, 3508. 
6. Uriel, C.; Ventura, J.; Gómez, A. M.; López, J. C.; Fraser-Reid, B. J. Org. Chem. 2012, 77, 795. 
7. Berglund, J.; Bouckaert, J.; De Greve, H.; Knight, S. WO Patent 2005089733 A2, 2005. 
8. (a) Sueshkumar, G.; Hotha, S. Tetrahedron Lett. 2007, 48, 6564. (b) Lopez, J. C.; Uriel, C.; 
Guillamon-Martin, A.; Valverde, S.; Gomez, A. M. Org. Lett., 2007, 9, 2759. 
9. Rodebaugh, R.; Joshi, S.; Fraser-Reid, B.; Geysen, H. M. J. Org. Chem. 1997, 62, 5660. 
10. Pastore, A.; Adinolfi, M.; Iadonisi, A. Eur. J. Org. Chem. 2008, 36, 6206. 
11. (a) Li, Y.; Yang, X.; Liu, Y.; Zhu, C.; Yang, Y.; Yu, B. Chem. Eur. J. 2010, 16, 1871. (b) Madsen, 
R.; Fraser-Reid, B. J. Org. Chem. 1995, 60, 772. 
 
 
Table S1. MALDI-TOF data of sugar derivatives and (glyco)peptoids. 
 
entry compound MS (calcd.) MS (obs.) ([M+Na]+) 
1 16 388.1 411.1 
2 17 402.2 425.2 
3 18 416.2 439.2 
4 19 416.2 439.2 
5 20 636.2 659.3 
6 21 650.7 673.3 
7 22 664.7 687.3 
8 23 664.7 687.2 
9 24 636.2 659.0 
S12 
 
10 25 650.7 673.1 
11 26 664.7 687.2 
12 27 664.7 687.3 
13 28 636.2 659.3 
14 29 650.7 673.3 
15 30 664.7 687.2 
16 31 481.3 504.4 
17 32 495.3 518.2 
18 33 1089.4 1112.9 
19 34 1103.4 1126.5 
20 35 1103.4 1126.3 
21 36 1117.5 1140.6 
22 37 270.3 293.2 
23 38 892.9 915.6 
24 39 855.4 878.5 
25 40 869.4 892.5 
26 41 883.4 906.7 
27 42 883.4 906.7 
28 43 1131.5 1154.5 
29 44 1131.5 1154.5 
30 45 1103.4 1126.6 
31 46 1117.5 1140.6 
32 47 1131.5 1154.5 
33 48 1131.5 1154.5 
34 49 642.4 665.6 
35 50 1250.5 1273.2 
36 51 1264.5 1287.2 
37 52 1278.5 1302.5 
38 53 1250.5 1273.7 
39 54 1264.5 1287.4 
40 55 1278.5 1301.5 
41 56 1250.5 1273.8 
42 57 1264.5 1287.5 
43 58 1278.5 1302.0 
44 59 599.7 622.3 






































































entry peptoid sugar catalyst solvent temp. (oC) time product conv. (%) 
1 31 20 G1 DCM 40 8 h 33 <5 
2 31 20 G2 DCM 40 8 h 33 <5 
3 31 20 HG2 DCM 40 8 h 33 13 
4 31 20 G1 DCB µwave 3 min. 33 <5 
5 31 20 G2 DCB µwave 3 min. 33 <5 
6 31 20 HG2 DCB µwave 3 min. 33 <5 
7 31 21 G1 DCM 40 8 h 34 <5 
8 31 21 G2 DCM 40 8 h 34 10 
9 31 21 HG2 DCM 40 8 h 34 29 
10 31 21 G1 DCB µwave 3 min. 34 <5 
11 31 21 G2 DCB µwave 3 min. 34 <5 
12 31 21 HG2 DCB µwave 3 min. 34 20 
13 32 20 G1 DCM 40 8 h 35 10 
14 32 20 G2 DCM 40 8 h 35 <5 
15 32 20 HG2 DCM 40 8 h 35 27 
16 32 20 G1 DCB µwave 3 min. 35 <5 
17 32 20 G2 DCB µwave 3 min. 35 <5 
18 32 20 HG2 DCB µwave 3 min. 35 <5 
19 32 21 G1 DCM 40 8 h 36 18 
20 32 21 G2 DCM 40 8 h 36 22 
21 32 21 HG2 DCM 40 8 h 36 47 
22 32 21 G1 DCB µwave 3 min. 36 <5 
23 32 21 G2 DCB µwave 3 min. 36 <5 
































Reagents and conditions: a. (i) sugar derivative (20 equiv, 25 mM), HG2 (5 mol %), DCM, 40 °C; 





















1H, 13C NMR spectra of new compounds 
 
 



























































































































































































Figure S16. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 36.  

































































































































Figure S18. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 40.  

































































































































Figure S20. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 42.  





























































































































Figure S22. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 44. 
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Figure S24. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 46. 
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Figure S26. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 48. 
  























































































































Figure S27. (a) HPLC chromatograms and (b) MALDI-TOF spectrum of compound 50.  




































































Rink Amide AM (0.4 mmol/g) 
20 (25 mM) 
Rink Amide AM (0.2 mmol/g) 






















































































































Rink Amide AM (0.2 mmol/g) 
21 (75 mM) 
Rink Amide AM (0.2 mmol/g) 
21 (25 mM) 
Rink Amide AM (0.2 mmol/g) 
21 (50 mM) 
Rink Amide AM (0.4 mmol/g) 
21 (25 mM) 
Rink Amide AM (0.2 mmol/g) 









Figure S29. (a) HPLC chromatograms and (b) MALDI-TOF spectrum of compound 52. 
  







































































Rink Amide AM (0.4 mmol/g) 
22 (25 mM) 
Rink Amide AM (0.2 mmol/g) 














Figure S31. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 54.  








































































































































Figure S33. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 56.  






































































































































Figure S35. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 58.  















































































































































Figure S37. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 61. 
  





































































































































Figure S39. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 63. 
  











































































































Figure S41. (a) HPLC chromatogram and (b) MALDI-TOF spectrum of compound 65. 
  











































1270.41871074.8409 1470.79791000.1587 1147.0041 1396.14511332.5270 1559.99021249.85291080.8059 1477.61431172.4517 1395.40561329.2353 1565.3069































































































Figure S42. Comparison of HPLC chromatograms of glycopeptoid (57) 
 









































Glu 1. 0.5 M NaOMe, 50% MeOH/THF





Figure S43. MALDI-TOF spectrum of glycopeptoid (57-1) 
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